CytoDyn announces first site in the southeastern USA to enroll patients in Phase 2 coronavirus trial

The Novant Health network cares for around 5 million patients a year at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial using leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms. Novant Health is the second trial site in the USA and the first site in the southeastern US to initiate this Phase 2 trial. Earlier on Wednesday, it was reported that the death toll from the virus in the US now stands at nearly 13,000 and there were nearly 2,000 deaths between Tuesday and Wednesday. New York state alone recorded 731 deaths on Tuesday.